Nivolumab, a human IgG4 programmed death 1 (PD-1) immune checkpoint–inhibitor antibody, disrupts PD-1–mediated signaling and restores antitumor immunity (1). Many recent studies have emphasized the importance of anti–PD-1 antibodies to improve survival outcomes among patients with advanced melanoma or lung cancer. Several endocrinological side effects have been reported and a few patients developed insulin-requiring diabetes (2). Some …

中文翻译：

---

反计划死亡1（PD-1）抗体与胰腺：糖尿病风暴即将来临？

Nivolumab是一种人类IgG4程序性死亡1（PD-1）免疫检查点抑制剂抗体，可破坏PD-1介导的信号传导并恢复抗肿瘤免疫力（1）。最近的许多研究都强调了抗PD-1抗体对于改善晚期黑色素瘤或肺癌患者的生存结果的重要性。已经报道了几种内分泌学副作用，并且一些患者发展了需要胰岛素的糖尿病（2）。一些 …